HUP9904023A3 - Use of leptin antagonists for treating insulin resistance in type ii diabetes - Google Patents
Use of leptin antagonists for treating insulin resistance in type ii diabetesInfo
- Publication number
- HUP9904023A3 HUP9904023A3 HU9904023A HUP9904023A HUP9904023A3 HU P9904023 A3 HUP9904023 A3 HU P9904023A3 HU 9904023 A HU9904023 A HU 9904023A HU P9904023 A HUP9904023 A HU P9904023A HU P9904023 A3 HUP9904023 A3 HU P9904023A3
- Authority
- HU
- Hungary
- Prior art keywords
- diabetes
- type
- insulin resistance
- treating insulin
- leptin antagonists
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 2
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 102000016267 Leptin Human genes 0.000 title 1
- 108010092277 Leptin Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title 1
- 229940039781 leptin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19638487 | 1996-09-20 | ||
| PCT/EP1997/005035 WO1998012224A1 (en) | 1996-09-20 | 1997-09-15 | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9904023A2 HUP9904023A2 (hu) | 2000-03-28 |
| HUP9904023A3 true HUP9904023A3 (en) | 2002-01-28 |
Family
ID=7806282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9904023A HUP9904023A3 (en) | 1996-09-20 | 1997-09-15 | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6399745B1 (hu) |
| EP (1) | EP0956302A1 (hu) |
| JP (1) | JP2001500869A (hu) |
| KR (1) | KR20010029537A (hu) |
| CN (1) | CN1230966A (hu) |
| AR (1) | AR008444A1 (hu) |
| AU (1) | AU735178B2 (hu) |
| BR (1) | BR9711513A (hu) |
| CA (1) | CA2266585A1 (hu) |
| CZ (1) | CZ90999A3 (hu) |
| HU (1) | HUP9904023A3 (hu) |
| ID (1) | ID21861A (hu) |
| IL (1) | IL129057A0 (hu) |
| NO (1) | NO991186L (hu) |
| PL (1) | PL332458A1 (hu) |
| RU (1) | RU2201249C2 (hu) |
| WO (1) | WO1998012224A1 (hu) |
| ZA (1) | ZA978455B (hu) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000007014A2 (en) * | 1998-07-28 | 2000-02-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Leptin-mediated gene-induction |
| US6777388B1 (en) | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| US7208572B2 (en) | 1998-08-21 | 2007-04-24 | Albany Medical College | Leptin-related peptides |
| US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| CA2388417A1 (en) | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| CA2407872C (en) | 2000-05-22 | 2013-11-12 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Receptor-based interaction trap |
| US7235629B2 (en) | 2000-11-14 | 2007-06-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Functional fragment of the leptin receptor |
| CN103897066A (zh) | 2004-02-11 | 2014-07-02 | 安米林药品有限责任公司 | 具有可选择特性的杂合多肽 |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| US7407929B2 (en) * | 2004-05-07 | 2008-08-05 | Boston Biomedical Research Institute | Leptin peptide antagonists |
| US7423113B2 (en) | 2004-08-25 | 2008-09-09 | Vib Vzw | Leptin antagonist |
| US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| BRPI0518241A (pt) | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| EA011653B1 (ru) | 2005-02-11 | 2009-04-28 | Амилин Фармасьютикалз, Инк. | Аналоги и гибридные полипептиды gip с избираемыми свойствами |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| WO2007112069A2 (en) * | 2006-03-23 | 2007-10-04 | Amylin Pharmaceuticals, Inc. | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| AU2007360979B2 (en) * | 2007-11-14 | 2014-04-10 | Amylin Pharmaceuticals, Llc | Methods for treating obesity and obesity related diseases and disorders |
| US8778890B2 (en) | 2009-03-31 | 2014-07-15 | Temple University—Of the Commonwealth System of Higher Education | Leptin antagonist and methods of use |
| JP2012523434A (ja) | 2009-04-10 | 2012-10-04 | アミリン・ファーマシューティカルズ，インコーポレイテッド | エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物 |
| EA032917B1 (ru) | 2010-09-28 | 2019-08-30 | Амилин Фармасьютикалс, Ллк | Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия |
| CN103957926B (zh) | 2011-07-08 | 2018-07-03 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
| EP2900230B1 (en) | 2012-09-27 | 2018-08-15 | The Children's Medical Center Corporation | Compounds for the treatment of obesity and methods of use thereof |
| ES2709976T3 (es) | 2013-11-26 | 2019-04-22 | Childrens Medical Ct Corp | Compuestos para el tratamiento de la obesidad y procedimientos de uso de los mismos |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CN104829708B (zh) * | 2015-05-06 | 2017-11-28 | 广东省生物资源应用研究所 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
| CN104829707B (zh) * | 2015-05-06 | 2017-12-19 | 广东省生物资源应用研究所 | 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用 |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| CA3036551A1 (en) | 2016-09-12 | 2018-03-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
| EP3675961A1 (en) * | 2017-08-31 | 2020-07-08 | University Of Dundee | Leptin peptides and their use for treating neurological disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5569743A (en) * | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5574133A (en) * | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) * | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5563243A (en) * | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5525705A (en) * | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| JPH11508895A (ja) * | 1995-06-30 | 1999-08-03 | イーライ・リリー・アンド・カンパニー | 糖尿病を処置する方法 |
| US7063958B1 (en) * | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| US5922678A (en) * | 1996-06-28 | 1999-07-13 | Eli Lilly And Company | Methods for treating diabetes |
-
1997
- 1997-09-15 JP JP10514270A patent/JP2001500869A/ja active Pending
- 1997-09-15 RU RU99107759/14A patent/RU2201249C2/ru not_active IP Right Cessation
- 1997-09-15 IL IL12905797A patent/IL129057A0/xx unknown
- 1997-09-15 HU HU9904023A patent/HUP9904023A3/hu unknown
- 1997-09-15 EP EP97942929A patent/EP0956302A1/en not_active Withdrawn
- 1997-09-15 CZ CZ99909A patent/CZ90999A3/cs unknown
- 1997-09-15 CN CN97198076A patent/CN1230966A/zh active Pending
- 1997-09-15 PL PL97332458A patent/PL332458A1/xx unknown
- 1997-09-15 BR BR9711513A patent/BR9711513A/pt not_active Application Discontinuation
- 1997-09-15 ID IDW990105A patent/ID21861A/id unknown
- 1997-09-15 CA CA002266585A patent/CA2266585A1/en not_active Abandoned
- 1997-09-15 AU AU44586/97A patent/AU735178B2/en not_active Ceased
- 1997-09-15 US US09/147,805 patent/US6399745B1/en not_active Expired - Fee Related
- 1997-09-15 WO PCT/EP1997/005035 patent/WO1998012224A1/en not_active Application Discontinuation
- 1997-09-15 KR KR1019997002389A patent/KR20010029537A/ko not_active Application Discontinuation
- 1997-09-18 AR ARP970104293A patent/AR008444A1/es unknown
- 1997-09-19 ZA ZA9708455A patent/ZA978455B/xx unknown
-
1999
- 1999-03-11 NO NO991186A patent/NO991186L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU735178B2 (en) | 2001-07-05 |
| AR008444A1 (es) | 2000-01-19 |
| ID21861A (id) | 1999-08-05 |
| EP0956302A1 (en) | 1999-11-17 |
| CN1230966A (zh) | 1999-10-06 |
| NO991186D0 (no) | 1999-03-11 |
| CA2266585A1 (en) | 1998-03-26 |
| US6399745B1 (en) | 2002-06-04 |
| PL332458A1 (en) | 1999-09-13 |
| KR20010029537A (ko) | 2001-04-06 |
| JP2001500869A (ja) | 2001-01-23 |
| AU4458697A (en) | 1998-04-14 |
| ZA978455B (en) | 1998-03-20 |
| HUP9904023A2 (hu) | 2000-03-28 |
| BR9711513A (pt) | 1999-08-24 |
| WO1998012224A1 (en) | 1998-03-26 |
| CZ90999A3 (cs) | 1999-06-16 |
| RU2201249C2 (ru) | 2003-03-27 |
| IL129057A0 (en) | 2000-02-17 |
| NO991186L (no) | 1999-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9904023A3 (en) | Use of leptin antagonists for treating insulin resistance in type ii diabetes | |
| HK1031174A1 (en) | Compositions and methods for treating diabetes | |
| IL125131A0 (en) | Retractable needle and syringe combination | |
| ZA976598B (en) | IGF-I and insulin formulation | |
| HU9503045D0 (en) | Heterocyclic compounds and their preparation and use | |
| HUP0004170A3 (en) | Methods and materials for treating and preventing inflammation ofmucosal tissue | |
| EG21712A (en) | Treatment of insulin resistance | |
| EP0788489A4 (en) | HETEROCYCLIC COMPOUNDS AND THEIR USE | |
| IL133136A0 (en) | Use of leptin antagonists for the treatment of diabetes | |
| AU1967897A (en) | Method for treatment of insulin resistance | |
| GB9606076D0 (en) | Diabetes treatment | |
| GB9824160D0 (en) | Heterocyclic compounds and their therapeutic use | |
| HK1042253A1 (zh) | 化合物及其用於治療糖尿病並發症的用途 | |
| PL337220A1 (en) | Application of leptin antagonists in treating diabetes | |
| AU5709698A (en) | Methods for treating insulin resistance and identifying patients at risk for thedisease | |
| SI1007085T1 (en) | Use of growth hormone in compositions for treating insulin resistance in the heart | |
| EP1161242A4 (en) | COMPOSITION AND METHOD FOR TREATING DIABETES | |
| GB9625449D0 (en) | Compounds for use in medicine | |
| AU5408099A (en) | Electrically treated composition and use thereof | |
| ZA976215B (en) | Novel treatment of leptin resistance | |
| GB9423948D0 (en) | Heterocyclic compounds, their preparation and their therapeutic use | |
| GB9415175D0 (en) | Heterocyclic compounds, their preparation and their therapeutic use | |
| GB9414350D0 (en) | Heterocyclic compounds, their preparation and their therapeutic use | |
| IL118696A0 (en) | Precise dosage syringe | |
| ZA972790B (en) | Heterocyclic compounds and their preparation and use. |